Leaky Gut Triggers Atrial Fibrillation in Aging via a Key Stress Kinase
New research reveals how gut barrier breakdown activates cardiac JNK2, driving age-related atrial fibrillation through inflammation.
Summary
Atrial fibrillation (AF) is the most common heart rhythm disorder and becomes far more prevalent with age. Researchers at Ohio State and Rush University have discovered a molecular link between a leaky gut and AF: a stress-activated enzyme called JNK2. When the gut barrier breaks down — as commonly happens with aging — inflammatory signals like TNF-α, IL-17A, and bacterial lipopolysaccharide leak into the bloodstream and activate JNK2 in heart tissue. This triggers abnormal calcium handling in atrial cells, causing the electrical misfires that lead to AF. In mouse models, restoring gut barrier integrity, blocking JNK2, or neutralizing TNF-α all reduced AF risk. The findings position JNK2 as a central hub connecting gut inflammation to heart arrhythmia, and suggest new therapeutic targets for a condition that affects millions of older adults.
Detailed Summary
Atrial fibrillation affects tens of millions of people worldwide and is a leading cause of stroke and heart failure, with risk rising sharply after age 65. Despite its prevalence, current treatments are often inadequate, and the biological mechanisms driving age-related AF remain incompletely understood. This study, published in Circulation, identifies a previously underappreciated pathway linking gut health to heart rhythm disorders.
The research team investigated whether the stress-activated kinase JNK2 serves as a molecular integrator connecting gut-derived inflammatory signals to atrial arrhythmia. They used three complementary mouse models: naturally aged mice, mice with chemically induced leaky gut (dextran sulfate sodium), and mice with genetic knockdown of occludin — a key tight junction protein that maintains gut barrier integrity.
Across all three models, leaky gut conditions robustly activated JNK2 in atrial tissue. This activation triggered a cascade of abnormal calcium handling events — including diastolic calcium leak from the sarcoplasmic reticulum, calcium waves, and delayed afterdepolarizations — all of which are known drivers of AF. Crucially, restoring gut barrier function reduced AF susceptibility. Pharmacological inhibition of JNK2 or blockade of TNF-α similarly abolished the increased AF risk, confirming the pathway's causal role.
The study also demonstrates for the first time that leaky gut-associated mediators — specifically TNF-α, IL-17A, and lipopolysaccharide — directly activate cardiac JNK2, establishing a mechanistic gut-to-heart axis. This helps explain why systemic inflammation in aging correlates with AF risk, even when prior clinical studies on inflammation and AF have yielded inconsistent results.
These findings have significant implications for both prevention and treatment. Interventions that preserve gut barrier integrity — including dietary strategies, probiotics, or targeted therapies — may reduce AF burden in older adults. JNK2 inhibition emerges as a novel and specific therapeutic target. Limitations include the preclinical nature of the work and reliance on mouse models, which may not fully recapitulate human AF pathophysiology.
Key Findings
- Leaky gut activates cardiac JNK2, which drives calcium dysregulation and increases atrial fibrillation susceptibility in aged mice.
- Restoring gut barrier integrity significantly reduced AF inducibility in a clinically relevant mouse model.
- TNF-α blockade or JNK2 inhibition abolished leaky gut-associated AF risk, confirming a causal pathway.
- TNF-α, IL-17A, and lipopolysaccharide from a leaky gut directly activate cardiac JNK2 — a novel mechanistic finding.
- JNK2 acts as a nodal stress integrator linking systemic gut-derived inflammation to arrhythmogenic calcium dysfunction.
Methodology
The study used three mouse models: naturally aged mice, dextran sulfate sodium-induced leaky gut mice, and intestinal occludin-knockdown (OD+/-) mice. Physiological and molecular assays assessed gut barrier function, atrial JNK2 activation, calcium handling, and AF inducibility. Pharmacological interventions included JNK2 inhibitors and TNF-α blockade.
Study Limitations
This is a preclinical study conducted entirely in mouse models, and findings may not directly translate to human AF pathophysiology. The summary is based on the abstract only, as the full text was not available, limiting assessment of methodological detail and statistical rigor. The relative contribution of each inflammatory mediator (TNF-α vs. IL-17A vs. LPS) to JNK2 activation in humans remains to be established.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.